Presentation is loading. Please wait.

Presentation is loading. Please wait.

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Published byLewis Aspden Modified over 9 years ago

Similar presentations

Presentation on theme: "Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)"— Presentation transcript:

1 Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

2 Background. Surgical atrial ablation procedure (MAZE) may restore sinus rhythm (SR) in pts with atrial fibrillation (AF) undergoing cardiac surgery. Hypothesis (formulated by cardiac surgeons): (1)MAZE restores SR after surgery (2)without increasing perioperative complications (3)SR presence may improve long term outcomes.

3 Methods Prospective randomized open multicenter study Primary efficacy outcome: SR presence (without any AF episode) during 24-hours ECG after 1 year. Primary safety outcome at 30 days: death / myocardial infarction / stroke / renal failure. Main secondary outcome: composite of death, major bleeding, stroke or hospitalization for heart failure after 1 and 5 years.

4 Patients Inclusion criteria: Heart team indication for cardiac surgery AF documented at least twice in last six months - paroxysmal or (long standing) persistent signed informed consent age over 18 years. Exclusion criteria: Emergent surgery 224 pts with AF scheduled for valvular and/or coronary surgery MAZE group (left atrial surgical ablation, n=117) Non-MAZE group (no ablation, n=107)

5 Baseline characteristic n (%)MAZE (n = 117)Non-MAZE (n = 107) Age (years)69.9 ± 7.871.0 ± 7.9 Paroxysmal AF26 (22.2)33 (30.8) Persistent AF30 (25.6)25 (23.4) Longstanding persistent AF61 (52.1)49 (45.8) Atrial fibrillation just prior surgery91 (77.8)70 (65.4) Left atrial diameter (mm)48.7 ± 7.347.7 ± 7.1 Mean NYHA functional class2.3 ± 0.62.3 ± 0.7 Prior stroke / TIA13 (11.1)15 (14.0) Diabetes41 (35.0)40 (37.4) Prior major bleeding4 (3.4)6 (5.6) Ejection fraction (%)52.6 ± 10.949.9 ± 12.5 Logistic EuroSCORE5.8 (3.2-9.9)6.8 (4.0-11.6)

6 Surgical procedure Cryomaze (ATS) in 97% pts, radiofrequency in 3% pts. Ablation time for each lesion 90 seconds. Lesion set: pulmonary veins ablation, left atrial appendage exclusion and three interconnecting lesions Epicardially or endocardially (based on whether LA is opened during the main surgical procedure)

7 Procedure types (all-comers with AF)

8 Sinus rhythm after 1 year (primary efficacy end-point, Holter 24-hour ECG) p = 0,002 p = 1.000 p = 0,194 p< 0,001

9 Evolution of sinus rhytm during 1 year (12-lead ECGs)

10 Perioperative complications Primary safety outcome (death / myocardial infarction / stroke / renal failure at 30 days) p = 0,411

11 Long-term adverse events (Death/ major bleeding/ stroke/ hospitalization for heart failure after 1 year) p = 0,785 p = 0,800 p = 0,654 p = 0,319 p = 0,680

12 Secondary outcomes at 1 year p=0,825 p=0,887 p=0,174

13 Conclusions (1) Surgical ablation improves the likelihood of SR presence up to 1 year postoperatively (2) Without perioperative complications (3) No impact on 1-year clinical outcomes Most significant rhythm benefit in pts with longstanding persistent AF (no benefit seen in paroxysmal AF).

Download ppt "Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)"

Similar presentations

Linoxsmart S DX Master Study

Linoxsmart S DX Master Study
Steroids In caRdiac Surgery (SIRS) Trial

Steroids In caRdiac Surgery (SIRS) Trial
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
1/ Incidence of AF: 5% of the population > 60 years, - 600 000 candidates for AF surgery in USA 2/ Etiologies: among patients applying for a life insurance:

1/ Incidence of AF: 5% of the population > 60 years, candidates for AF surgery in USA 2/ Etiologies: among patients applying for a life insurance:
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First Line Treatment in 294 Patients with Paroxysmal.

A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First Line Treatment in 294 Patients with Paroxysmal.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370:2467-2477 Presented by Kris Huston | July 21, 2014.

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Can we prevent stent restenosis after coronary stent implantation

Can we prevent stent restenosis after coronary stent implantation
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY

FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
FFR vs Angiography for Multivessel Evaluation

FFR vs Angiography for Multivessel Evaluation
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.

Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial O.
Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,

Optimal Method and Outcomes of Catheter Ablation of Persistent AF: The STAR AF 2 Trial Atul Verma, Jiang Chen-yang, Tim Betts, John Radcliffe, Jian Chen,
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Final Three-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer The.

Final Three-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer The.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.

Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.

INTERVENTIONAL TREATMENT OF ATRIAL FIBRILLATION St. Mary’s Hospital February – August 2007.
Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.

Clinical Title Date Jaret Tyler, MD Clinical Cardiac Electrophysiologist Assistant Professor of Medicine Ohio State’s Heart and Vascular Center Atrial.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.

Similar presentations

Ads by Google